《Journal Of Experimental & Clinical Cancer Research》期刊

杂志介绍

JCR分区

中科院分区

1区

影响因子

14.3

CiteScore

22.3

期刊收录

SCI、SCIE

Journal Of Experimental & Clinical Cancer Research（中文译名：《实验与临床癌症研究杂志》），ISSN：1756-9966，EISSN：1756-9966，是BioMed Central出版的国际性学术期刊，创刊于2008年，以Quarterly形式稳定发行，2026年总发文量约317篇。该刊采用OA开放访问，学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物，已被SCI（科学引文索引）、SCIE（科学引文索引扩展版）等国际主流学术数据库收录。2026年期刊影响因子达14.3，2025年期刊CiteScore为22.3，2025年期刊自引率约1.4%，在中科院期刊分区体系中位列医学大类1区TOP 期刊，在所属学科领域具备高学术影响力与国际认可度。Journal Of Experimental & Clinical Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿，平均审稿周期约1月，审稿流程高效稳定。在稿件录用评判中，该刊将创新性与前沿性作为核心遴选标准，重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看，CHINA MAINLANDUSA、Italy、Taiwan、GERMANY (FED REP GER)、South Korea、Spain等为核心发文国家与地区；

期刊评价

名词解释：

影响因子（Impact Factor, IF）：指该期刊前两年发表的文章，在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区：中科院分区表是国内主流的学术期刊分级评价工具，核心意义是建立跨学科可比的统一评价标尺，为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据，同时帮助科研人员筛选优质期刊、规避学术风险，适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》（2026年3月发布）

大类学科	小类学科	Top期刊	综述期刊
医学 1区	ONCOLOGY 肿瘤学 1区	是	否

期刊分区表（2025年3月升级版）

大类学科	小类学科	Top期刊	综述期刊
医学 1区	ONCOLOGY 肿瘤学 1区	是	否

期刊分区表（2023年12月升级版）

大类学科	小类学科	Top期刊	综述期刊
医学 1区	ONCOLOGY 肿瘤学 2区	是	否

JCR分区

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	23 / 333	93.2
学科：ONCOLOGY	SCIE	Q1	20 / 333	94.14

2024-2025年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	23 / 328	93.1
学科：ONCOLOGY	SCIE	Q1	20 / 328	94.05

中国学者近期发文

Ferrodoxin 1 (FDX1) drives paclitaxel resistance in ovarian cancer via copper metabolism and ULK1/ATG13-mediated autophagy: overcome by pH/ROS-responsive PPD/PDP@si-FDX1 nanomicelle

Author:Gong, Yangmei; Deng, Zhizhi; Wu, Jie; Hu, Yi

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-025-03589-z

Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling (Vol 38, 426, 2019

Author:Ou, Baochi; Sun, Hongze; Zhao, Jingkun; Xu, Zhuoqing; Liu, Yuan; Feng, Hao; Peng, Zhihai

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03714-6

Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway (vol 37, 41, 2018

Author:Hu, Xiang; Li, Ya-Qi; Li, Qing-Guo; Ma, Yan-Lei; Peng, Jun-Jie; Cai, San-Jun

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03704-8

RETRACTION: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathwa

Author:Liu, Bing; Pan, Shimeng; Xiao, Yang; Liu, Qianqian; Xu, Jingchao; Jia, Li

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03700-y

UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1 (vol 38, 297, 2019

Author:Chen, Hongze; Li, Le; Hu, Jisheng; Zhao, Zhongjie; Ji, Liang; Cheng, Chundong; Zhang, Guangquan; Zhang, Tao; Li, Yilong; Chen, Hua; Pan, Shangha; Sun, Bei

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03696-5

Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemi

Author:Shen, Jie; Jin, Peng; Liang, Yebing; Zhu, Jinyang; Xiang, Rufang; Li, Zeyi; Zhu, Hongming; Li, Xiaoyang; Zhang, Yunxiang; Wang, Wei; Jin, Zhen; Li, Junmin

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03689-4

Repurposing dronedarone induces ferroptosis through GPX4 inactivation and degradation in pancreatic cance

Author:Gu, Yanmei; Wang, Yingying; Liu, Gangli; Cui, Rong; Ma, Chenzhe; Wang, Jianrong; Gao, Xing; Zhao, Yang; Li, Yumin

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03687-6

LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activatio

Author:Bai, Guannan; Zhang, Lin; Zhao, Manli; Zhang, Jingyao; Chen, Wenhao

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03691-w

USP1 driven mitotic dysregulation and PLK1 stabilization confer Lenvatinib resistance in hepatocellular carcinom

Author:Qiang, Yuwei; Bian, Saiyan; Tong, Yun; Chen, Weiting; Tang, Zhangzhi; Dai, Chengchen; Liu, Mingyu; Xu, Banglong; Jiang, Lihan; Ma, Kexin; He, Xuyang; Li, Jinlong; Xiao, Mingbing; Zheng, Wenjie

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03683-w

Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cance

Author:Wang, Zi-Wen; Zhang, Xu; Wang, Yu-Xin; Cai, Meng-Yuan; Chen, Jiao; Sang, Ming-Yi; Yang, Hai-Yan; Shi, Liang; Wei, Ji-Fu; Ding, Qiang

Journal: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2026; Vol. 45, Issue 1, pp. -. DOI: 10.1186/s13046-026-03686-7